Clinical Trials in Atlanta

Showing 4641-4660 of 19,805 trials

A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

NCT06208878

This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies

CRISPR Therapeutics AG70 participantsStarted Nov 2023

Duarte, California, United States • Los Angeles, California, United States • Stanford, California, United States +19 more locations

Active Not RecruitingPhase 2< 1 mile

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

NCT03314181

This is a study of venetoclax, daratumumab, and dexamethasone with and without bortezomib combination therapy to evaluate safety, tolerability, and efficacy of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Part 1 includes participants with t(11;14) positive relapsed/refractory (R/R) multiple myeloma who will receive venetoclax in combination with daratumumab and dexamethasone (VenDd); Part 2 includes participants with R/R multiple myeloma who will receive venetoclax in combination with daratumumab, bortezomib, and dexamethasone (VenDVd); Part 3 includes participants with t(11;14) positive R/R multiple myeloma who will receive venetoclax in combination with daratumumab and dexamethasone (VenDd) or daratumumab, bortezomib, and dexamethasone (DVd). Part 1 and Part 2 are non-randomized and will be initiated with a dose-escalation phase in which increasing doses of venetoclax will be given with fixed doses of daratumumab and dexamethasone (Part 1a) or with fixed doses of daratumumab, bortezomib, and dexamethasone (Part 2a). Each dose escalation phase will be followed by a single-arm, open-label expansion phase. Part 3 will include a randomized, open-label expansion phase with participants receiving venetoclax in combination with daratumumab and dexamethasone (VenDd) or daratumumab, bortezomib, and dexamethasone (DVd).

Multiple Myeloma

AbbVie156 participantsStarted Apr 2018

Aurora, Colorado, United States • Tampa, Florida, United States • Atlanta, Georgia, United States +37 more locations

A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

Find Trials by Condition in Atlanta

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients

ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus

INSPIRE Trial for Abdominal Infections

A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

Air Optix Plus HydraGlyde Multifocal Daily/Extended Wear Contact Lenses

Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix

A Real-World Evidence (RWE) Long-Term Follow-Up Study to Assess Outcomes of Alcon Monofocal Intraocular Lenses

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Evaluation of Non-Invasive Tests for Metabolic Liver Disease

Topical ENS-002 for Atopic Dermatitis in Adults

Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours